Skip to main content

Table 1 Patient baseline characteristics of NPC patients before PSM

From: Effectiveness and cost-effectiveness analysis of nimotuzumab for the radiotherapy of locoregionally advanced nasopharyngeal carcinoma

Characteristic NTZ group
N = 50 (%)
Non-NTZ group
N = 344 (%)
P value
Gender 0.870
 Male 34 (68.00) 240 (69.77)  
 Female 16 (32.00) 104 (30.23)  
Age 0.387
 ≤ 50 33 (66.00) 205 (59.59)  
 > 50 17 (34.00) 139 (40.41)  
T classification 0.763
 T1 6 (12.00) 34 (9.88)  
 T2 7 (14.00) 50 (14.53)  
 T3 20 (40.00) 138 (40.17)  
 T4 17 (34.00) 122 (35.47)  
N classification 0.855
 N0 3 (6.00) 30 (8.72)  
 N1 17 (34.00) 111 (32.27)  
 N2 18 (36.00) 119 (34.59)  
 N3 12 (24.00) 84 (24.42)  
Clinical stage 0.840
 III 23 (46.00) 153 (44.48)  
 IV 27 (54.00) 191 (55.52)